Navigation Links
Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments

BOSTON, March 24, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has strengthened its current line of Laparoscopic surgical instruments in order to better align its product offerings with current global endoscopy market trends.

Solos has focused its R & D efforts into the design and development of new modifications to its endoscopic instrument lines to accommodate the continual advances in Laparoscopic surgical procedures including bile duct reconstruction, laparoscopic adrenalectomy and distal pancreatectomy, amongst a host of other operations and diagnostic applications. The significant advances over the past several years have led to a number of advantages to the patient with laparoscopic surgery versus an open procedure (laparotomy). These advantages include reduced pain due to smaller incisions and hemorrhaging, and shorter recovery time.

According to, the market for endoscopy devices is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.5% from 2009-2015, with growth driven by innovations in endoscopy technology and expansion of indications suitable for endoscopic surgery. The article went on to acknowledge that laparoscopy is the largest segment, contributing 27% to the global endoscopy market and is projected to grow at a CAGR of 8% until 2015, becoming the largest growth opportunity in endoscopy.

"We are highly enthusiastic regarding the prospects for Solos' next generation portfolio of endoscopic and laparoscopic instrumentation, which are expected to provide the opportunity to regain momentum and expand our revenue growth," stated Bob Segersten, President of Solos Endoscopy, Inc.

The Company expects to post its full unaudited financial results for the fiscal year ended December 31, 2010 on the OTC Markets Group website within in the next week.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at:

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. To Introduce New Urology Instrument Line
2. Solos Endoscopy, Inc. Reports $34,291 in Sales Revenue for January 2011
3. Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
4. Solos Endoscopy, Inc. Trends toward Strong Continued Growth in 2011
5. Solos Endoscopy, Inc. Announces Recapitalization Plan for 2011
6. Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010
7. Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting
8. Solos Endoscopy, Inc. to Hold Annual Shareholder Meeting September 28, 2010
9. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
10. Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
11. Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth
Post Your Comments:
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):